Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Capricor Therap (CAPR)

Capricor Therap (CAPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,994
  • Shares Outstanding, K 3,736
  • Annual Sales, $ 1,670 K
  • Annual Income, $ -15,190 K
  • 60-Month Beta 1.79
  • Price/Sales 4.92
  • Price/Cash Flow N/A
  • Price/Book 3.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.79
  • Number of Estimates 1
  • High Estimate -0.79
  • Low Estimate -0.79
  • Prior Year -1.10
  • Growth Rate Est. (year over year) +28.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.86 +3.22%
on 11/12/19
2.91 -34.02%
on 10/16/19
-0.58 (-23.20%)
since 10/11/19
3-Month
1.86 +3.22%
on 11/12/19
3.80 -49.47%
on 10/01/19
-1.10 (-36.42%)
since 08/12/19
52-Week
1.86 +3.22%
on 11/12/19
9.50 -79.79%
on 11/16/18
-7.38 (-79.35%)
since 11/12/18

Most Recent Stories

More News
Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CAPR : 1.92 (-10.28%)
Capricor: 3Q Earnings Snapshot

BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $1.6 million in its third quarter.

CAPR : 1.92 (-10.28%)
Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update

Provides Update on End of Phase Type-B Meeting with FDA

CAPR : 1.92 (-10.28%)
Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7

Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other...

CAPR : 1.92 (-10.28%)
Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Call Scheduled for Thursday, October 24 at 10:30am Eastern Time

CAPR : 1.92 (-10.28%)
CHF Solutions System to be Used in JAHVH Study After Final Nod

CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.

SYK : 200.18 (+0.89%)
CAPR : 1.92 (-10.28%)
GWPH : 109.40 (-3.38%)
CHFS : 0.70 (-3.13%)
Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months

--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies--

CAPR : 1.92 (-10.28%)
Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?

Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.

GWPH : 109.40 (-3.38%)
CAPR : 1.92 (-10.28%)
ZYXI : 9.09 (+1.00%)
NTRP : 0.71 (unch)
Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET

Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD)...

CAPR : 1.92 (-10.28%)
Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System

Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.

ABT : 84.34 (+0.69%)
GWPH : 109.40 (-3.38%)
CAPR : 1.92 (-10.28%)
NTRP : 0.71 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CAPR with:

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

2nd Resistance Point 2.20
1st Resistance Point 2.06
Last Price 1.92
1st Support Level 1.82
2nd Support Level 1.72

See More

52-Week High 9.50
Fibonacci 61.8% 6.58
Fibonacci 50% 5.68
Fibonacci 38.2% 4.78
Last Price 1.92
52-Week Low 1.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar